stockrow
Friday 6 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +200.5%
Quarter to September 2026, against a year earlier
12.19
1.17
+10.62%
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) EV/Sales
As of 6 November 2026, Vir Biotechnology, Inc. (VIR) trades at a EV/Sales of 5.3×. Over the past ten years it has ranged from −20.5× (November 2019) to 475× (June 2020); the current reading is higher than 61% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.3× | 7,352.72% |
| FY2024 | 0.1× | — |
| FY2023 | −1.5× | — |
| FY2022 | 0.6× | (87.22%) |
| FY2021 | 4.3× | (86.54%) |
| FY2020 | 32.0× | — |
| FY2019 | −1.0× | — |
| FY2018 | −18.2× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 4.7× | 22.12% |
| Jun 2026 | 3.9× | (69.88%) |
| Mar 2026 | 12.9× | 140.61% |
| Dec 2025 | 5.3× | (68.34%) |
| 28 more quarters | Free account |
Against its own ten years
Low −20.5×
High 475×
Ten-year median
2.9×
Current reading's percentile
50
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 0.9× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.3× |
| VIR Vir Biotechnology, Inc. | 5.3× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.7× |
| MESO Mesoblast Limited compare | 147× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)